Abstract
Drug delivery through mouth is still the most acceptable route to administer bioactives for the patient. The colon targeted drug delivery has gained increasing attention towards the treatment of colorectal cancer and other colon related disorders i.e., Crohn's disease, ulcerative colitis, irritable bowel syndrome, and spastic colon. The drugs such as cardiovascular and antiasthmatic agents have also been delivered via colon to avoid first pass metabolism or acidic environment of stomach. Colon targeting has also been demonstrated as a potential tool for systemic delivery of protein/peptide drugs due to relatively low proteolytic activities in the colonic environment. The GIT is dwelt by over 500 bacterial species, each having a specific place in the tract and developing variety of enzymes which are being utilized for development of colon-targeted drug delivery systems. There are various strategies presently followed for colontargeted delivery i.e., prodrugs that become active at the colonic site, drug-eluting system reacting to the pH, microfloraactivated drug delivery systems, hydrogels and matrices, and multicoating time-dependent drug delivery systems. The future steering towards colon targeted bioactives delivery would involve the application of specific binding with colonic mucosa.
Keywords: CDDS, colon specific drug delivery, nanoparticle, prodrug.
Current Drug Therapy
Title:Colon as Target for Drug Delivery
Volume: 9 Issue: 1
Author(s): Anamika Sahu, Aviral Jain and Arvind Gulbake
Affiliation:
Keywords: CDDS, colon specific drug delivery, nanoparticle, prodrug.
Abstract: Drug delivery through mouth is still the most acceptable route to administer bioactives for the patient. The colon targeted drug delivery has gained increasing attention towards the treatment of colorectal cancer and other colon related disorders i.e., Crohn's disease, ulcerative colitis, irritable bowel syndrome, and spastic colon. The drugs such as cardiovascular and antiasthmatic agents have also been delivered via colon to avoid first pass metabolism or acidic environment of stomach. Colon targeting has also been demonstrated as a potential tool for systemic delivery of protein/peptide drugs due to relatively low proteolytic activities in the colonic environment. The GIT is dwelt by over 500 bacterial species, each having a specific place in the tract and developing variety of enzymes which are being utilized for development of colon-targeted drug delivery systems. There are various strategies presently followed for colontargeted delivery i.e., prodrugs that become active at the colonic site, drug-eluting system reacting to the pH, microfloraactivated drug delivery systems, hydrogels and matrices, and multicoating time-dependent drug delivery systems. The future steering towards colon targeted bioactives delivery would involve the application of specific binding with colonic mucosa.
Export Options
About this article
Cite this article as:
Sahu Anamika, Jain Aviral and Gulbake Arvind, Colon as Target for Drug Delivery, Current Drug Therapy 2014; 9 (1) . https://dx.doi.org/10.2174/1574885509666140805003632
DOI https://dx.doi.org/10.2174/1574885509666140805003632 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design Current and Future Applications of Probiotics
Current Nutrition & Food Science East-West Fusion–Necrosis and Apoptosis Acting in Concert by Demethylcantharidin-Integrated Platinum Complexes
Anti-Cancer Agents in Medicinal Chemistry Cancer T Cell Immunotherapy with Bispecific Antibodies and Chimeric Antigen Receptors
Recent Patents on Anti-Cancer Drug Discovery Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets The Use of L-Glucose in Cancer Diagnosis: Results from In Vitro and In Vivo Studies
Current Medicinal Chemistry Synthesis of Silica Based Nanoparticles Against the Proliferation of Human Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetics and In Vivo Fate of Drug Loaded Chitosan Nanoparticles<sup>++</sup>
Current Drug Metabolism Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD)
Reviews on Recent Clinical Trials Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma
Current Cancer Drug Targets Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy Rational Drug Development Using Gene-Targeted Agents and Their Application in Anti-Gene Radiotherapy
Current Genomics Effects of Tea Polyphenols and their Polymers on MAPK Signaling Pathways in Cancer Research
Mini-Reviews in Medicinal Chemistry FAK and p53 Protein Interactions
Anti-Cancer Agents in Medicinal Chemistry Strategies to Overcome Drug Resistance of Receptor Tyrosine Kinaseaddicted Cancer Cells
Current Medicinal Chemistry A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Medicinal Chemistry Epigenomics
Current Drug Metabolism New Insight into P-Glycoprotein as a Drug Target
Anti-Cancer Agents in Medicinal Chemistry Up-regulated Circulating miR-106a by DNA Methylation Promised a Potential Diagnostic and Prognostic Marker for Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry